# Phase 1 Lymphoma, Follicular trials recruiting: 45 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 45 trials in phase 1 for Lymphoma, Follicular that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Lymphoma, Follicular trials: 45 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/lymphoma-follicular

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 45
- Recruiting or not yet: 45
- Read on: November 19, 2026

## Trials

The 25 newest of 45, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07941492 | A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma | Weill Medical College of Cornell University | Phase 1 | Not yet recruiting | Follicular Lymphoma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941492) |
| October 20, 2026 | NCT07883941 | Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883941) |
| October 1, 2026 | NCT07853040 | A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment | Incyte Corporation | Phase 1 | Recruiting | Hepatic Insufficiency, Liver Diseases | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853040) |
| September 28, 2026 | NCT07844967 | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844967) |
| July 9, 2026 | NCT07691606 | A Study of ARC-02 in B-cell NHL | Taiho Oncology, Inc. | Phase 1 | Recruiting | B-cell Non Hodgkin Lymphoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691606) |
| June 10, 2026 | NCT07638982 | Axatilimab + CAR-T for High-Risk Lymphoma | Northside Hospital, Inc. | Phase 1 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell... | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638982) |
| June 5, 2026 | NCT07630545 | A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients. | Mission Therapeutics | Phase 1 | Recruiting | Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630545) |
| April 30, 2026 | NCT07559474 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe... | Incyte Corporation | Phase 1 | Recruiting | Hepatic Insufficiency, Liver Diseases | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559474) |
| April 24, 2026 | NCT07550634 | Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment | MindRank AI Ltd | Phase 1 | Not yet recruiting | Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550634) |
| April 23, 2026 | NCT07546760 | A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 | AstraZeneca | Phase 1 | Recruiting | Hepatic Impairment | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546760) |
| February 20, 2026 | NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424833) |
| February 20, 2026 | NCT07422610 | Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment | Novartis Pharmaceuticals | Phase 1 | Recruiting | Advanced Malignancies and Hepatic Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07422610) |
| January 15, 2026 | NCT07343934 | huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma | University of Pennsylvania | Phase 1 | Recruiting | Relapsed or Refractory Follicular Lymphoma | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07343934) |
| November 12, 2025 | NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | Eli Lilly and Company | Phase 1 | Recruiting | Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226843) |
| November 6, 2025 | NCT07225439 | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225439) |
| August 14, 2025 | NCT07121946 | This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma | LTZ Therapeutics, Inc. | Phase 1 | Recruiting | Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL)... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07121946) |
| August 11, 2025 | NCT07114939 | FTT PET/CT in Pancreatic Neuroendocrine Tumors | Abramson Cancer Center at Penn Medicine | Phase 1 | Recruiting | Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07114939) |
| August 3, 2025 | NCT07101328 | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF\_FRontier-1 ) | Eli Lilly and Company | Phase 1 | Recruiting | Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell... | 215 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07101328) |
| June 17, 2025 | NCT07024147 | JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma | Peking University Cancer Hospital & Institute | Phase 1 | Not yet recruiting | B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma, Marginal Zone B Cell Lymphoma, Mantle... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024147) |
| May 20, 2025 | NCT06980116 | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980116) |
| March 6, 2025 | NCT06860594 | Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | National Cancer Institute (NCI) | Phase 1 | Recruiting | Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06860594) |
| March 5, 2025 | NCT06859008 | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory... | City of Hope Medical Center | Phase 1 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic... | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859008) |
| February 7, 2025 | NCT06815029 | Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or... | City of Hope Medical Center | Phase 1 | Recruiting | Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06815029) |
| January 3, 2025 | NCT06756490 | A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation | Sichuan Huiyu Pharmaceutical Co., Ltd | Phase 1 | Recruiting | Moderate or Severe Submental Fullness | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06756490) |
| December 2, 2024 | NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | Mayo Clinic | Phase 1 | Recruiting | Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06712810) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Nurix Therapeutics, Inc. | 2 |
| Mayo Clinic | 2 |
| City of Hope Medical Center | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 2 |
| Abramson Cancer Center at Penn Medicine | 1 |
| Medical College of Wisconsin | 1 |
| University of Pennsylvania | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| LTZ Therapeutics, Inc. | 1 |
| Weill Medical College of Cornell University | 1 |
| National Cancer Institute (NCI) | 1 |
| Aurigene Discovery Technologies Limited | 1 |
| Northside Hospital, Inc. | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| GenomeFrontier Therapeutics TW Co., Ltd. | 1 |
| University of Florida | 1 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 1 |
| Verismo Therapeutics | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| Accutar Biotechnology Inc | 1 |
| Sichuan Huiyu Pharmaceutical Co., Ltd | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| [Taiho Oncology, Inc.](https://specstream.ai/data/clinical-trials/company/taiho-oncology-inc) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 35 |
| Spain | 9 |
| Poland | 7 |
| France | 7 |
| Italy | 7 |
| China | 6 |
| United Kingdom | 6 |
| Australia | 5 |
| Japan | 3 |
| Germany | 3 |
| South Korea | 2 |
| Moldova | 2 |
| Ukraine | 2 |
| Canada | 2 |
| India | 1 |
| Bulgaria | 1 |
| Russia | 1 |
| Taiwan | 1 |
| Netherlands | 1 |
| Switzerland | 1 |
| Romania | 1 |
| Georgia | 1 |
| Greece | 1 |
| Denmark | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Countertop installers in the United States](https://specstream.ai/data/businesses/countertop-installers/united-states)
- [Periodontics practices in the United States](https://specstream.ai/data/businesses/periodontics-practices/united-states)
- [Broadcast media production companies in the United States](https://specstream.ai/data/businesses/broadcast-media-production-companies/united-states)
- [Medical supply stores in the United States](https://specstream.ai/data/businesses/medical-supply-stores/united-states)
- [Australian restaurants in the United States](https://specstream.ai/data/businesses/australian-restaurants/united-states)
- [Inspection companies in the United States](https://specstream.ai/data/businesses/inspection-companies/united-states)
